## Fabio Trippa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7579666/publications.pdf

Version: 2024-02-01

471061 360668 1,232 41 17 35 citations h-index g-index papers 46 46 46 1728 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Stereotactic radiotherapy for oligometastases in the lymph nodes. Reports of Practical Oncology and Radiotherapy, 2022, 27, 46-51.	0.3	2
2	Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 273-279.	0.7	3
3	Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy. Ochsner Journal, 2021, 21, 301-305.	0.5	O
4	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. Medical Oncology, 2021, 38, 72.	1.2	6
5	Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review. Radiotherapy and Oncology, 2021, 163, 55-67.	0.3	9
6	Twelve-year results of LINAC-based radiosurgery for vestibular schwannomas. Strahlentherapie Und Onkologie, 2020, 196, 40-47.	1.0	4
7	Long-term palliation of lymph node oligometastatic ovarian carcinoma after repeated stereotactic body radiotherapy: case report. Tumori, 2020, 106, NP63-NP66.	0.6	4
8	Hypofractionated radiotherapy for complicated bone metastases in patients with poor performance status: a phase II international trial. Tumori, 2019, 105, 181-187.	0.6	9
9	Accelerated partial-breast irradiation with high-dose-rate brachytherapy: Mature results of a Phase II trial. Brachytherapy, 2019, 18, 627-634.	0.2	2
10	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. European Urology, 2019, 76, 732-739.	0.9	99
11	Positron emission tomography for staging locally advanced cervical cancer and assessing intensity modulated radiotherapy approach. Radiologia Medica, 2019, 124, 819-825.	4.7	2
12	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World Journal of Urology, 2019, 37, 2631-2637.	1.2	69
13	A prospective phase II trial on reirradiation of brain metastases with radiosurgery. Clinical and Translational Radiation Oncology, 2019, 17, 1-6.	0.9	8
14	No paradigm changes with checkpoint inhibitor monotherapy in patients with metastatic renal cell carcinoma and brain metastases. Annals of Translational Medicine, 2019, 7, 612-612.	0.7	0
15	Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World Journal of Urology, 2017, 35, 45-49.	1.2	61
16	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. British Journal of Cancer, 2017, 116, 1520-1525.	2.9	121
17	The vicious circle of treatment-induced toxicities in locally advanced head and neck cancer and the impact on treatment intensity. Critical Reviews in Oncology/Hematology, 2017, 116, 82-88.	2.0	9
18	Partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. Long-term results of a phase II prospective study. Radiotherapy and Oncology, 2017, 124, 208-213.	0.3	25

#	Article	IF	Citations
19	Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy. European Urology Focus, 2017, 3, 538-544.	1.6	39
20	Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer. Journal of Contemporary Brachytherapy, 2017, 2, 118-123.	0.4	13
21	Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre crossâ€sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study. BJU International, 2016, 117, 867-873.	1.3	23
22	Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study. Urology, 2016, 96, 165-170.	0.5	21
23	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	2.0	51
24	Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements Critical Reviews in Oncology/Hematology, 2016, 100, 147-166.	2.0	112
25	Breakthrough Pain Management in Patients Undergoing Radiotherapy: A National Survey on Behalf of the Palliative and Supportive Care Study Group. Tumori, 2015, 101, 603-608.	0.6	6
26	Long-term outcome of moderate hypofractionated stereotactic radiotherapy for meningiomas. Strahlentherapie Und Onkologie, 2015, 191, 953-960.	1.0	14
27	Spinal Cord and Cauda Equina Compression. Cancer Metastasis - Biology and Treatment, 2014, , 309-321.	0.1	O
28	Stereotactic fractionated radiotherapy for post-surgery progressive or recurrent craniopharyngioma. Journal of Radiation Oncology, 2013, 2, 401-406.	0.7	0
29	Diarrhoea in irradiated patients: A prospective multicentre observational study. Digestive and Liver Disease, 2013, 45, 933-937.	0.4	9
30	Prevention and Treatment of Bone Metastases in Breast Cancer. Journal of Clinical Medicine, 2013, 2, 151-175.	1.0	12
31	Reirradiation of brain metastases with radiosurgery. Radiotherapy and Oncology, 2012, 102, 192-197.	0.3	41
32	Reirradiation of metastatic spinal cord compression: Definitive results of two randomized trials. Radiotherapy and Oncology, 2011, 98, 234-237.	0.3	39
33	Treatment of Recurrent Glioblastoma with Stereotactic Radiotherapy: Long-Term Results of a Mono-Institutional Trial. Tumori, 2011, 97, 56-61.	0.6	35
34	Tumor Relapse or Radionecrosis After Radiosurgery: Single-Photon Emission Computed Tomography for Differential Diagnosis. In Regard to Blonigen etÂal. Irradiated Volume as a Predictor of Brain Radionecrosis After Linear Accelerator Stereotactic Radiosurgery. (Int J Radiat Oncol Biol Phys) Tj ETQq0 0 0 rgB	T /Overloc	k 18 Tf 50 13:
35	A prospective observational trial on emesis in radiotherapy: Analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiotherapy and Oncology, 2010, 94, 36-41.	0.3	84
36	8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: Results of a phase III randomized multicentre Italian trial. Radiotherapy and Oncology, 2009, 93, 174-179.	0.3	187

## FABIO TRIPPA

#	Article	IF	CITATIONS
37	Be Careful in Getting Cost-Effectiveness Conclusions From a Debatable Trial!. International Journal of Radiation Oncology Biology Physics, 2007, 68, 314.	0.4	9
38	Raltitrexed and Radiotherapy as Adjuvant Treatment for Stage II-III Rectal Cancer: A Feasibility Study. Tumori, 2005, 91, 498-504.	0.6	1
39	Re-irradiation of brain metastases and metastatic spinal cord compression: clinical practice suggestions. Tumori, 2005, 91, 325-30.	0.6	14
40	Management of Metastatic Spinal Cord Compression. Tumori, 2003, 89, 469-475.	0.6	47
41	Management of metastatic spinal cord compression. Tumori, 2003, 89, 469-75.	0.6	13